May 6th 2025
The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung cancer (SCLC), but it was also linked to higher rates of serious adverse events like cytokine release syndrome than seen in clinical trials.
Watch the series now!
Expert Insights: Most Popular Videos, Interviews, and Podcasts in 2016
Dr Joseph Alvarnas Discusses Clinical Risk in Value-Based Cancer Care
How Can Practices Seek Success With Oncology Payment Reform?
Preventing Chemotherapy-Associated Alopecia: A Case for Palliation?
Smoking Cessation Programs Need a Boost Under Medicaid Expansion